Headlands Research has announced the acquisition of an established clinical research site, now known as Headlands Research Eastern Massachusetts. The site has specialized in neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease for over 25 years.
Headlands Research Eastern Massachusetts is led by founder and Principal Investigator (PI) Donald Marks, MD, a board-certified neurologist specializing in the diagnosis and treatment of Alzheimer’s disease, Parkinson’s disease, and related disorders who also currently serves on the staff of the Division of Neurology at Beth Israel Deaconess Hospital—Plymouth. Marks conducted his first clinical trial in 1993, evaluating tacrine, the first drug approved for the treatment of Alzheimer’s disease, and in 2008, Marks and his team began research on disease-modifying drugs (DMDs) for Alzheimer’s disease. To date, Marks and his team have conducted 41 clinical trials, with 36 focusing on Alzheimer’s disease. The team has been in an accelerated growth phase—13 of the 36 Alzheimer’s disease trials have been started since 2020.
Headlands Research Acquires Established Eastern Massachusetts–Based Research Site Specializing in Neurodegenerative Diseases. (2023, April 18). Business Wire.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.